Literature DB >> 12208978

Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215.

P P Chamberlain1, J Ren, C E Nichols, L Douglas, J Lennerstrand, B A Larder, D I Stuart, D K Stammers.   

Abstract

Six structures of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) containing combinations of resistance mutations for zidovudine (AZT) (M41L and T215Y) or lamivudine (M184V) have been determined as inhibitor complexes. Minimal conformational changes in the polymerase or nonnucleoside RT inhibitor sites compared to the mutant RTMC (D67N, K70R, T215F, and K219N) are observed, indicating that such changes may occur only with certain combinations of mutations. Model building M41L and T215Y into HIV-1 RT-DNA and docking in ATP that is utilized in the pyrophosphorolysis reaction for AZT resistance indicates that some conformational rearrangement appears necessary in RT for ATP to interact simultaneously with the M41L and T215Y mutations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12208978      PMCID: PMC136500          DOI: 10.1128/jvi.76.19.10015-10019.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Improved methods for building protein models in electron density maps and the location of errors in these models.

Authors:  T A Jones; J Y Zou; S W Cowan; M Kjeldgaard
Journal:  Acta Crystallogr A       Date:  1991-03-01       Impact factor: 2.290

2.  Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants.

Authors:  J Lennerstrand; K Hertogs; D K Stammers; B A Larder
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Processing of X-ray diffraction data collected in oscillation mode.

Authors:  Z Otwinowski; W Minor
Journal:  Methods Enzymol       Date:  1997       Impact factor: 1.600

4.  Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase.

Authors:  P L Boyer; S G Sarafianos; E Arnold; S H Hughes
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

5.  A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase.

Authors:  P R Meyer; S E Matsuura; A M Mian; A G So; W A Scott
Journal:  Mol Cell       Date:  1999-07       Impact factor: 17.970

6.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

Review 7.  Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs).

Authors:  N Sluis-Cremer; D Arion; M A Parniak
Journal:  Cell Mol Life Sci       Date:  2000-09       Impact factor: 9.261

8.  Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids.

Authors:  S G Sarafianos; K Das; A D Clark; J Ding; P L Boyer; S H Hughes; E Arnold
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

9.  Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.

Authors:  P Kellam; C A Boucher; J M Tijnagel; B A Larder
Journal:  J Gen Virol       Date:  1994-02       Impact factor: 3.891

10.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.

Authors:  L A Kohlstaedt; J Wang; J M Friedman; P A Rice; T A Steitz
Journal:  Science       Date:  1992-06-26       Impact factor: 47.728

View more
  24 in total

1.  Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodeficiency virus type 1 reverse transcriptase with increased activity against thymidine analogue-resistant mutants.

Authors:  Peter R Meyer; Anthony J Smith; Suzanne E Matsuura; Walter A Scott
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

2.  Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.

Authors:  Johan Lennerstrand; Chung K Chu; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

3.  Solution characterization of [methyl-(13)C]methionine HIV-1 reverse transcriptase by NMR spectroscopy.

Authors:  Xunhai Zheng; Geoffrey A Mueller; Eugene F DeRose; Robert E London
Journal:  Antiviral Res       Date:  2009-08-07       Impact factor: 5.970

4.  Towards discovering dual functional inhibitors against both wild type and K103N mutant HIV-1 reverse transcriptases: molecular docking and QSAR studies on 4,1-benzoxazepinone analogues.

Authors:  Zhenshan Zhang; Mingyue Zheng; Li Du; Jianhua Shen; Xiaomin Luo; Weiliang Zhu; Hualiang Jiang
Journal:  J Comput Aided Mol Des       Date:  2006-08-08       Impact factor: 3.686

5.  Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.

Authors:  Zixin Hu; Françoise Giguel; Hiroyu Hatano; Patrick Reid; Jing Lu; Daniel R Kuritzkes
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.

Authors:  Yasushi Tojo; Yasuhiro Koh; Masayuki Amano; Manabu Aoki; Debananda Das; Sarang Kulkarni; David D Anderson; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

7.  Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.

Authors:  Paul L Boyer; Tomozumi Imamichi; Stefan G Sarafianos; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors.

Authors:  Janice D Pata; William G Stirtan; Steven W Goldstein; Thomas A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

9.  The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.

Authors:  Antonio J Acosta-Hoyos; Walter A Scott
Journal:  Viruses       Date:  2010-01-28       Impact factor: 5.048

10.  Structural similarity-based predictions of protein interactions between HIV-1 and Homo sapiens.

Authors:  Janet M Doolittle; Shawn M Gomez
Journal:  Virol J       Date:  2010-04-28       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.